Th e study of phosphate homeostasis has received far less attention than calcium homeostasis for many decades. In part this is because phosphate is abundantly available in the diet whereas calcium is limited. However, there is increasing evidence that regulation of serum levels of phosphate through absorption in the intestine and excretion and reabsorption in the kidney is critical -for example, during growth, in hyperphosphatemia associated with chronic renal failure, and in X-linked hypophosphatemia. In classical endocrine regulation, low serum phosphate induces the renal production of the seco-steroid hormone 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ). Low serum calcium signals the parathyroid glands to release parathyroid hormone (PTH), which likewise signals the kidney to increase production of 1,25(OH) 2 D 3 . Th is active metabolite of vitamin D acts to restore circulating mineral levels by increasing absorption in the intestine, reabsorption in the kidney, and mobilization of calcium and phosphate from bone. Th us, chronic renal failure is associated with hyperparathyroidism, which in turn contributes to osteomalacia.
Another complication of chronic renal failure is hyperphosphatemia. Because the kidney is compromised in its ability to excrete phosphate, research has been devoted to assessing intestinal phosphate transport in nephrectomized rat model systems. Marks et al. 1 (this issue) have, for the fi rst time, studied the eff ect of diet on such a model system in vivo. Uptake experiments using in situ intestinal loops showed that duodenal transport was greater than that in the jejunum but was unaff ected by nephrectomy. Th e lower level of transport in the jejunum may be due to greater retention as measured in vitro. A low-phosphate diet tended to decrease transport in vivo but did not achieve a statistically significant diff erence. Expression of Na/Pi-IIb cotransporter mRNA was also unaffected by experimental manipulation in the intestine. In contrast, kidneys served as 'positive' controls in that this tissue showed diff erences in Na/Pi-IIa transporter mRNA levels with nephrectomy and diet. Th e authors go on to note several therapeutic interventions that might be useful, such as the compound JTP-59557, a triazole derivative that inhibits Na/Pi-IIb.
Fibroblast growth factor 23 (FGF-23) has recently been recognized as a key mediator of phosphate homeostasis, its most notable eff ect being promotion of phosphate excretion. FGF-23 was discovered to be involved in diseases such as autosomal dominant hypophosphatemic rickets, X-linked hypophosphatemia, and tumor-induced osteomalacia in which phosphate wasting was coupled to inappropriately low levels of 1,25(OH) 2 A complicating fac tor is that 24,25(OH) 2 D 3 also decreases calcium transport in the intestine 9,10 and indeed has been found to be hypocalcemic in both dogs 11 and rats. 12 
